Dan Hennings Preclinical data to be presented at AACR will showcase the potential effect of D-4559, a potent macrophage switching nanomedicine, on reducing tumor growth in a mouse model of hepatocellular carcinoma, a type of liver cancer Ashvattha will present preclinical data at ARVO on its oral formulation of D-4517.2, a potent anti-angiogenic nanomedicine, in a laser-induced … Read more
– The study will evaluate the safety, tolerability and ability of [18F]OP-801 to cross the blood brain barrier and selectively target neuroinflammation in individuals with ALS and healthy volunteers– REDWOOD CITY, Calif., February 6, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel nanomedicines called hydroxyl dendrimer therapeutics (HDT), today announced that the … Read more
REDWOOD CITY, Calif., January 3, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class of precision medicines, today announced that the Company will provide a corporate overview at Biotech Showcase 2023 taking place in San Francisco, California, from January 9-11, 2023. Presenter Jeffrey Cleland, … Read more
– Scientific collaborators at Stanford University will present data on an imaging and treatment regimen demonstrating the microglial targeting of [18F]OP-801 in a mouse model of multiple sclerosis and the synthesis of [18F]OP-801 for the ongoing clinical trial – REDWOOD CITY, Calif., September 15, 2022 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel … Read more
– First patient was enrolled as part of a two-stage Phase 2 study evaluating Ashvattha’s subcutaneous (SC) anti-VEGF wet AMD and DME candidate, D-4517.2 – – The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously (SC) administered D-4517.2 compared to intravitreal (IVT) injection of aflibercept, … Read more
– Data showed OP-101 delivered intravenously may have the potential to treat systemic inflammation and neuronal injury, reducing morbidity and mortality in hospitalized patients with severe COVID-19 – REDWOOD CITY, Calif., July 25, 2022 – Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced the publication of the results from … Read more
– Scientific collaborators at Stanford University will present preclinical data on the sensitivity of [18F]OP-801 in comparison to TSPO-PET for detecting early-stage neuroinflammation – REDWOOD CITY, Calif., July 18, 2022 – Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data on the sensitivity of … Read more
Scientific collaborators at Indiana University School of Medicine presented preclinical data showing Ashvattha’s hydroxyl dendrimers (HDs) were selectively taken up only within tumor-associated microglia/macrophages in a mouse model of NF1 These findings suggest that therapeutic conjugation of HDs to target cells of plexiform neurofibroma (PNF) tumor microenvironment may be efficacious and minimize toxicity in the … Read more
– Scientific collaborators at Indiana University School of Medicine will present preclinical data demonstrating Ashvattha’s hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma – REDWOOD CITY, Calif., June 7, 2022 – Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating … Read more